Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Advanced sarcoma treatment is challenging due to limited effective therapies.
• Novel drug development for sarcoma is a critical area of research.
• Pan-phosphoinositide 3-kinase (PI3K) inhibitors are being investigated for cancer treatment.

Purpose of the Study:

• To evaluate the antitumor effects of the pan-PI3K inhibitor ZSTK474 in human sarcoma cell lines.
• To compare ZSTK474 with other PI3K inhibitors and clinically used sarcoma drugs.
• To investigate the efficacy of ZSTK474 in translocation-positive sarcoma models.

Main Methods:

• Developed a panel of 14 human sarcoma cell lines.
• Screened 24 anticancer agents, including ZSTK474 and other PI3K inhibitors.
• Assessed antiproliferative effects, PI3K-downstream pathway inhibition, and apoptosis induction.
• Conducted in vivo animal experiments to confirm antitumor activity.

Main Results:

• ZSTK474 demonstrated antiproliferative activity and inhibited PI3K-downstream pathways in all tested sarcoma cell lines.
• ZSTK474 selectively induced apoptosis in translocation-positive sarcoma cell lines (Ewing's, alveolar rhabdomyosarcoma, synovial sarcoma).
• In vivo studies confirmed ZSTK474's antitumor activity, with superior efficacy in translocation-positive models.

Conclusions:

• ZSTK474 exhibits potent antitumor activity against human sarcoma cell lines.
• The drug is particularly effective in sarcomas harboring chromosomal translocations.
• ZSTK474 represents a promising therapeutic candidate for advanced sarcomas, especially translocation-positive subtypes.